Search results: Sage Journals

Restricted accessOtherFirst published January, 1992

5Ht3 Receptor Antagonists Reverse the Cognitive Deficit Induced By Cerebral Ischaemia

Journal of Psychopharmacology

Open accessResearch articleFirst published September, 2024

Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms,function and cognition in early phase schizophrenia in a double-blind,2 × 2 factorial design,randomised controlled comparison with simvastatin

Imran B Chaudhry, Muhammad Omair Husain, Ameer B Khoso [...]

Journal of Psychopharmacology

Restricted accessOtherFirst published March, 1997

A comparison of the safety and efficacy of ondansetron versus granisetron as prophylaxis against chemo/ radiotherapy-induced nausea and vomiting in bone marrow transplantation patients. A double-blinded,randomized,prospective,pilot study

Reuven Or, Yosef Kupaluchnik, Pavlos Drakos [...]

Journal of Oncology Pharmacy Practice

Restricted accessOtherFirst published June, 1995

Current perspectives in the management of nausea and vomiting in oncology patients: The New Zealand experience

Bruce David Hastie

Journal of Oncology Pharmacy Practice

Restricted accessOtherFirst published September, 2011

Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting

Yu-Chen Yeh, Anne McDonnell, Elissa Klinger [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published November, 2014

Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY,a Prospective,Multicenter Study

Michele De Tursi, Consiglia Carella, Silverio Tomao [...]

Tumori Journal

Open accessReview articleFirst published 2017

Rolapitant in the Treatment of Nausea and Vomiting Associated With Chemotherapy

Ian N Olver

Clinical Medicine Insights: Therapeutics

Restricted accessResearch articleFirst published January, 2022

Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab

Emma Uchida, Matthew M Lei, Eric Roeland [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2017

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile

Kamesh Gupta, Harparam Singh Ghuman, Shivani Vijay Handa

Therapeutic Advances in Gastrointestinal Endoscopy

Restricted accessResearch articleFirst published August, 2026

Addition of an NK1 receptor antagonist to standard antiemetic prophylaxis in patients with B-cell lymphoma receiving EPOCH

Sloane English, Matthew Lei, Mark Sorial [...]

Journal of Oncology Pharmacy Practice

Restricted accessOtherFirst published January, 1992

5Ht3 Receptor Antagonists Reverse the Cognitive Deficit Induced By Cerebral Ischaemia

Journal of Psychopharmacology

Open accessResearch articleFirst published September, 2024

Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms,function and cognition in early phase schizophrenia in a double-blind,2 × 2 factorial design,randomised controlled comparison with simvastatin

Imran B Chaudhry, Muhammad Omair Husain, Ameer B Khoso [...]

Journal of Psychopharmacology

Restricted accessOtherFirst published March, 1997

A comparison of the safety and efficacy of ondansetron versus granisetron as prophylaxis against chemo/ radiotherapy-induced nausea and vomiting in bone marrow transplantation patients. A double-blinded,randomized,prospective,pilot study

Reuven Or, Yosef Kupaluchnik, Pavlos Drakos [...]

Journal of Oncology Pharmacy Practice

Restricted accessOtherFirst published June, 1995

Current perspectives in the management of nausea and vomiting in oncology patients: The New Zealand experience

Bruce David Hastie

Journal of Oncology Pharmacy Practice

Restricted accessOtherFirst published September, 2011

Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting

Yu-Chen Yeh, Anne McDonnell, Elissa Klinger [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published November, 2014

Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY,a Prospective,Multicenter Study

Michele De Tursi, Consiglia Carella, Silverio Tomao [...]

Tumori Journal

Open accessReview articleFirst published 2017

Rolapitant in the Treatment of Nausea and Vomiting Associated With Chemotherapy

Ian N Olver

Clinical Medicine Insights: Therapeutics

Restricted accessResearch articleFirst published January, 2022

Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab

Emma Uchida, Matthew M Lei, Eric Roeland [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2017

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile

Kamesh Gupta, Harparam Singh Ghuman, Shivani Vijay Handa

Therapeutic Advances in Gastrointestinal Endoscopy

Restricted accessResearch articleFirst published August, 2026

Addition of an NK1 receptor antagonist to standard antiemetic prophylaxis in patients with B-cell lymphoma receiving EPOCH

Sloane English, Matthew Lei, Mark Sorial [...]

Journal of Oncology Pharmacy Practice